- Home
- KFII vs TRVI Comparison
KFII vs TRVI Comparison
Compare KFII & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KFII
- TRVI
- Stock Information
- Founded
- KFII 2024
- TRVI 2011
- Country
- KFII United States
- TRVI United States
- Employees
- KFII N/A
- TRVI N/A
- Industry
- KFII
- TRVI Biotechnology: Pharmaceutical Preparations
- Sector
- KFII
- TRVI Health Care
- Exchange
- KFII NYSE
- TRVI Nasdaq
- Market Cap
- KFII 391.0M
- TRVI 383.4M
- IPO Year
- KFII 2025
- TRVI 2019
- Fundamental
- Price
- KFII $9.96
- TRVI $6.07
- Analyst Decision
- KFII
- TRVI Strong Buy
- Analyst Count
- KFII 0
- TRVI 8
- Target Price
- KFII N/A
- TRVI $17.56
- AVG Volume (30 Days)
- KFII 280.9K
- TRVI 1.6M
- Earning Date
- KFII 01-01-0001
- TRVI 05-06-2025
- Dividend Yield
- KFII N/A
- TRVI N/A
- EPS Growth
- KFII N/A
- TRVI N/A
- EPS
- KFII N/A
- TRVI N/A
- Revenue
- KFII N/A
- TRVI N/A
- Revenue This Year
- KFII N/A
- TRVI N/A
- Revenue Next Year
- KFII N/A
- TRVI N/A
- P/E Ratio
- KFII N/A
- TRVI N/A
- Revenue Growth
- KFII N/A
- TRVI N/A
- 52 Week Low
- KFII $9.90
- TRVI $2.30
- 52 Week High
- KFII $10.00
- TRVI $7.39
- Technical
- Relative Strength Index (RSI)
- KFII N/A
- TRVI 54.54
- Support Level
- KFII N/A
- TRVI $4.85
- Resistance Level
- KFII N/A
- TRVI $6.15
- Average True Range (ATR)
- KFII 0.00
- TRVI 0.50
- MACD
- KFII 0.00
- TRVI -0.04
- Stochastic Oscillator
- KFII 0.00
- TRVI 73.94
About KFII K&F GROWTH ACQUISITION CORP II
K&F Growth Acquisition Corp II is a special purpose acquisition company.
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.